Massive Upside In Big Money Pharma Favorite?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes in the use of immune therapies for cancer treatment. Specifically, Iovance is exploring new applications of tumor infiltrating lymphocyte (TIL) therapy, utilizing cells that the human body naturally produces to attack cancerous tumors.
There was lots of hype about this next-generation cancer treatment company but its share price has been decidedly lackluster this year, » Read more about: Massive Upside In Big Money Pharma Favorite? »
Read More
Brilliant Billionaire Buys Under-the-Radar Wide Moat Stock
In B2B sales and marketing, few companies have built as powerful a toolset as the one that caught Stan Druckenmiller’s eye.
With a unique moat in its vast proprietary database, accelerating AI-driven insights, and a growing foothold in emerging markets, this SaaS firm has become a must-have resource for enterprise sales teams.
Yet while bulls can point to a host of positive attributes,
» Read more about: Brilliant Billionaire Buys Under-the-Radar Wide Moat Stock »
Read More
Is Bitcoin $100,000 Next?
Bitcoin has been on a tear lately, bringing its YTD returns to over 112%. Much of this gain can be attributed to Donald Trump’s support of bitcoin and his electoral victory, which added to an already bullish period for Bitcoin.
Now, the big question is whether the benchmark cryptocurrency could cross the $100,000 mark for the first time in the near future.
» Read more about: Is Bitcoin $100,000 Next? »
Read More
Is Tesla In Nose-Bleed Territory?
Tesla has had a scintillating run since Election Day with the stock rallying from the low $220 region all the way towards $350+ in a matter of days.
Having run so far so fast, what are the odds Tesla share price is set to correct soon? How high is too high for Tesla stock price?
» Read more about: Is Tesla In Nose-Bleed Territory? »
Read More
1 Cloud SaaS Healthcare Stock to Buy on the Dip?
It might surprise many that Veeva Systems Inc. (NYSE:VEEV), best known for its cloud-based software solutions tailored to the life sciences industry, has maintained a core principle of putting customer success and product excellence ahead of short-term gains.
In a market crowded with SaaS companies seeking to serve a wide variety of enterprises,
» Read more about: 1 Cloud SaaS Healthcare Stock to Buy on the Dip? »
Read MoreThe Ivy
Up 10x Is Palantir Still a Deal?
Palantir Technologies (NASDAQ:PLTR) has been one of the undisputed victors in the AI boom and has defined the stock market for the past two years.
In the last 12 months alone, PLTR shares are up more than 350% on the back of rapid growth in the commercial business and tremendous investor enthusiasm for AI applications in the corporate world.
» Read more about: Up 10x Is Palantir Still a Deal? »
Read MoreThe Spotlight
1 High Energy Drink To Buy on the Dip?
Celsius Holdings (NASDAQ:CELH) is the maker of a line of energy drinks that has skyrocketed in popularity in recent years.
Once virtually unknown, Celsius has used social media marketing and celebrity influencer deals to rapidly build its brand awareness.
Although the product itself has been quite successful, the stock’s performance hasn’t matched it.
» Read more about: 1 High Energy Drink To Buy on the Dip? »
Read MoreThe Daily
New Gold Stock To Continue Outperformance In 2025
David focuses on growth & momentum stocks that are reasonably priced and likely to outperform the market over the long-term.
» Read more about: New Gold Stock To Continue Outperformance In 2025 »